Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: The BIGPRO1 study

Diabetes Care

Volumn 21, Issue 11, 1998, Pages 1967-1972

  Aline Charles, M ^a   Morange, Pierre ^a   Eschwège, Eveline ^a   André, Philippe ^a   Vague, Philippe ^b   Juhan Vague, Irène ^a  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; METFORMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADULT; AGED; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE POLYPEPTIDE ANTIGEN; TRIGLYCERIDES; VON WILLEBRAND FACTOR; WEIGHT LOSS;

EID: 3543065104     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.11.1967     Document Type: Article

References (40)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
3. Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Study Group: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris, Arteriosder Thromb 13:1865-1873, 1993
4. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ: Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342:1076-1079, 1993
5. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995
6. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996
7. Jansson JH, Nilsson TK, Olofsson BO: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7 year follow-up. Circulation 88:2030-2034, 1993
8. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwège E, the BIGPRO Study Group: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 19:920-926, 1996
9. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
10. Chakrabarti R, Hocking ED, Feamley GR: Fibrinolytic effect of metformin in coronary-artery disease. Lancet ii:256-259, 1965
11. Fearnley GR, Chakrabarti R, Evans JF: Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease. Lancet ii:1004-1007, 1968
12. Menon IS: Metformin and stanozolol in blood fibrinolytic activity. Br Med J 1:289-290, 1971
13. Grant PJ: The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diab Metab 17:168-173, 1991
14. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57:326-328, 1987
15. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-629, 1993
16. Ericksson E, Ranby M, Gyzander E, Risberg B: Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 50:91-101, 1988
17. Declerck PJ, Alessi MC, Verstreken M, Kruith of EKO, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme linked immunosorbent assay. Blood 71:220-225, 1988
18. Holvoet P, Cleemput H, Collen D: Assay of human tissue type plasminogen activator (t-PA) with an enzyme linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 54:684-687, 1985
19. Lindahl B, Asplund K, Eliasson M, Evrin PE: Insulin resistance syndrome and fibrinolytic activity: the Northern Sweden MONICA Study. Int J Epidemiol 25:291-299, 1996
20. Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Birkeland KI, Jenssen T: Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension, Arterioscler Thromb Vasc Biol 17:553-559, 1997
21. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA: Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo and hypertriglyceridaemic men. Diabetologia 36:817-825, 1993
22. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462, 1991
23. Alessi MC, Juhan-Vague I, Kooistra T, Declerk PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 60:491-494, 1988
24. Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E: Plasminogen activator inhibitor type-1 synthesis and mRNA expression in hepG2 cells are regulated by VLDL, Arterioscler Thromb Vasc Biol 16:89-96, 1996
25. Schneider DJ, Nordt TK, Sobel BE: Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 41:890-895, 1992
26. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
27. Nagi DK, Tracy R, Pratley R: Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism 45:1243-1247, 1996
28. Grant PJ, Kruithof EKO, Felly CP, Felber JP, Bachmann F: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79:516-516, 1990
29. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 93: 106-110, 1996
30. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997
31. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 2:800-803, 1996
32. Samad F, Yamamoto K, Lookutoff DJ: Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 97:37-46, 1996
33. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G: Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men, Arterioscler Thromb Vasc Biol 16:368-374, 1996
34. Schulman S, Lindmaker P, Johnsson H: Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. Blood Coagul Fibrinolysis 6:311-316, 1995
35. Landin K, Tengbom L, Smith U: Effects of metformin and metopolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost 71:783-787, 1994
36. Blann AD: Von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 50:125-134, 1993
37. Colantuoni A, Bertuglia S, Donato L: Effects of metformin on microvascular permeability in diabetic syrian hamsters, Diabete Metab 14:549-553, 1988
38. Bouskela E: Effects of metformin on the wing microcirculation of normal and diabetic bats. Diabete Metab 14:560-565, 1988
39. Valensi P, Behar A, Andre P, Wiernsperger N, Attali JR: The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema. Angiology 46:401-408, 1995
40. Sirtori CR: Clinical experience with metformin in patients with peripheral vascular disease. Diabete Metab 14:601-607, 1988